Ronald D’Amico

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 464 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Chloe Orkin, Shinichi Oka, Patrick Philibert et al. · The Lancet HIV · 2021 · 177 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 149 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Chloe Orkin, Enrique Bernal, Darrell H. S. Tan et al. · The Lancet HIV · 2021 · 142 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · Clinical Infectious Diseases · 2023 · 124 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17